Drugs / recombinant fowlpox-CEA(6D)/TRICOM vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00128622 | Sep 2005 → Mar 2007 | breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm | H. Kim Lyerly | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox-CEA(6D)/TRICOM vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00128622 ↗ |
| Known as | rF-CEA(6D)-TRICOM | “In a pilot study (n = 15), denileukin diftitox, given as a single dose or repeated dosing, was followed by immunizations with dendritic cells modified with the fowlpox vector...” PMID 18519811 ↗ Jun 2008 |
| Modality | Vaccine | “vaccine therapy” NCT00128622 ↗ |
| Route | Subcutaneous | “vaccine therapy comprising autologous DC infected with recombinant fowlpox-CEA (6D)-TRICOM vaccine intradermally and subcutaneously” NCT00128622 ↗ |